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Abstract
Objective: The aim of this study was to explore the extended family history of type
1 diabetes in children at genetic risk and define the impact of a positive family history
on the development of islet autoimmunity and type 1 diabetes.
Methods: The subjects were participants in The Finnish Type 1 Diabetes Prediction
and Prevention (DIPP) study and carried increased HLA-conferred risk for type 1 dia-
betes. The case children (N = 343) were positive for at least one islet autoantibody,
and the control children (N = 343) matched by age, gender and class II HLA genotype
were negative for islet autoantibodies at the time of data collection. Extended family
history of type 1 diabetes was obtained by using a structured questionnaire.
Results: Among children who were autoantibody positive and progressed to type
1 diabetes 62.2% (28/45) had at least one relative with type 1 diabetes. Interestingly,
57.8% of these children (26/45) had such a relative outside the nuclear family com-
pared to 30.7% of children with no autoantibodies (P = .001), 35.2% of those with
only classical islet cell antibodies (P = .006), and 35.2% of non-progressors with bio-
chemical autoantibodies (P = 0.011). A positive history of type 1 diabetes in the
paternal extended family was more common in children with multiple biochemical
autoantibodies compared to those with only one biochemical autoantibody
(P = .010). No association between the specificity of the first appearing autoantibody
and family history of the disease was found.
Conclusions: Type 1 diabetes in relatives outside the nuclear family is a significant
risk factor for islet autoimmunity and progression to clinical disease in HLA suscepti-
ble children.
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1 | INTRODUCTION
Type 1 diabetes is considered as an autoimmune disease caused by
interaction between genetic susceptibility and environmental factors.
Finland has the highest incidence of type 1 diabetes worldwide, and
in 2006 the peak incidence of 64.9/100000/year in children under
the age of 15 was reported.1
Type 1 diabetes has a subclinical phase identified by circulating islet
autoantibodies. There is, however, wide individual variation in the dura-
tion of the progression from islet autoimmunity to clinical diabetes.2
Observations from prospective follow-up studies starting from birth
have demonstrated that a substantial proportion of children who are
genetically at risk and progress to type 1 diabetes have developed islet
autoimmunity very early, between 9 months and 2 years of age.3-6 It
has also been observed that seroconversion occurs earlier and median
autoantibody levels are higher in children who progress to clinical type
1 diabetes before puberty.7-10 In all, over 80% of children with multiple
islet autoantibodies progress to symptomatic, insulin-requiring diabetes
within 15 years after developing multiple islet autoantibodies, whereas
only a minority of the children who remain positive for only a single islet
autoantibody develops type 1 diabetes.
Parental type 1 diabetes increases the risk of the child to develop
the disease.11-13 If the child has a father with type 1 diabetes, the dis-
ease risk is about two times higher when compared to a child who has a
mother with type 1 diabetes (6% vs 3%). The younger the age at the
onset of diabetes in the type 1 diabetic father the greater the risk of
the disease is in his offspring. The risk of type 1 diabetes is also
increased among the siblings of children with type 1 diabetes, and the
magnitude of this risk is dependent on the siblings' class II HLA geno-
type.14 Risk for islet autoimmunity is dramatically higher in DR3/4 sib-
lings who share both HLA haplotypes with their diabetic sibling
compared to siblings who do not share both of these HLA haplotypes
with the diabetic sibling.15,16 Less data is available on the role of a posi-
tive family history of type 1 diabetes in other family members than the
father, mother or siblings, that is, in relatives outside the nuclear family.
The aim of this study was to investigate the prevalence of type
1 diabetes in the extended families of children at increased HLA-
conferred disease risk and participating in the prospective Type 1 Dia-
betes Prediction and Prevention (DIPP) study in Finland, and compare
the development of islet autoimmunity and progression to type 1 dia-
betes in children with and without a positive family history of type
1 diabetes.
2 | METHODS
The Finnish DIPP study is a population-based prospective follow-
up study which was launched in 1994 and recruits all children born
in three University Hospitals in Finland (Oulu, Tampere and Turku)
for screening of class II HLA-conferred genetic susceptibility for
type 1 diabetes from cord blood. Children with eligible HLA geno-
types associated with increased risk are invited to participate in
follow-up until the age of 15 years with regular measurement of
autoantibodies against islet cells (ICA), insulin (IAA), GAD65
(GADA), and islet antigen 2 (IA-2A) from serum samples taken at
3 to 12 months' intervals. ICA was used as the primary screening
tool for islet autoimmunity until the end of 2002. If the child
turned positive to ICA or progressed to type 1 diabetes, all samples
taken during the follow-up were analyzed also for IAA, IA-2A and
GADA. Children born since 2003 have been regularly analyzed for
all four autoantibodies from all their samples. In addition, if the
child was found to be positive for any of the four above-
mentioned autoantibodies, zinc transporter 8 antibodies (ZnT8A)
have been measured from all samples of the child. Data on growth,
nutrition, and general health-related events including possible
medications has been recorded at the clinical study visits. In addi-
tion, information on family history of type 1 diabetes among first-
degree relatives (FDR, i.e. mother, father or sibling) has been
recorded at the time of birth and updated during the follow-up if
necessary.
2.1 | Genetic screening
HLA-conferred susceptibility to type 1 diabetes was screened cen-
trally at University of Turku using cord blood. Sequence specific
oligonucleotide probes specific for HLA-DQB1*02, DQB1*03:01,
DQB1*03:02 and DQB1*06:02/3 alleles were used initially, and
genotyping was step-wise expanded to cover more alleles in
DQB1 and DQA1 loci as well as DRB1*04 subtypes. The detailed
procedures have been described previously.5 The children in the
current study population were categorized into six groups
according to recent classification of HLA genotypes conferring
high, moderate, slightly increased, neutral, or slightly decreased
risk for type 1 diabetes, or protection for the disease according to
Ilonen et al 2016.17
2.2 | Autoantibody analyses
Islet cell antibodies (ICA), insulin autoantibodies (IAA), antibodies
against glutamic acid decarboxylase (GADA) and insulinoma anti-
gen (IA-2A) were analyzed in the Diabetes Research Laboratory at
the Department of Pediatrics, University of Oulu. Antibodies
against zinc transporter 8 (ZnT8A) were analyzed in the PEDIA lab-
oratory, University of Helsinki. DIPP participants who
seroconverted to positivity for any of these autoantibodies (ICA,
IAA, IA-2A, GADA or ZnT8A) were scheduled for follow-up visits
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at 3-month intervals. The age at seroconversion was defined as
the age at which at least one of the islet autoantibodies was
detected for the first time. The seroconversion to multiple autoan-
tibody positivity was defined as the age when at least two bio-
chemical (IAA, IA-2A, GADA or ZnT8A) autoantibodies were
detected in the same sample for the first time.
2.3 | Study design and participants
For the current analysis we invited a total of 343 DIPP families with
a child positive for at least one islet autoantibody (case family) to
answer the structured questionnaire of extended family history of
type 1 diabetes. In addition, we invited control families with a DIPP
child negative for islet autoantibodies and matched for date of
birth, sex and HLA-risk category with the DIPP child in the case
family. Qualification criteria for autoantibody negativity was that
no positive results had been obtained in samples collected from
birth until the date when extended family history data was col-
lected. All 343 case families and the 343 matched control families
were followed in the DIPP clinic at Oulu University Hospital and
received information about this survey by a trained study nurse
either at the DIPP visit or by an invitation letter. When informed
consent was received, data about the extended family history of
diabetes was collected between October 2003 and August 2008.
The data was not obtained from 47 case families and 30 control
families. Thus, our case control dataset included 296 and 313 chil-
dren with and without islet autoantibodies, respectively (Figure 1).
In the group of autoantibody positive children there were 177 chil-
dren who were positive for ICA but had no other islet autoanti-
bodies (ICA only).
Follow-up data until August 2016 was included (Figure 1). In the
group of autoantibody negative children 22 developed ICA only dur-
ing the follow-up, and another four children developed multiple bio-
chemical islet autoantibodies, and one of them progressed to type
1 diabetes. His age at seroconversion was 4.1 years and age at diag-
nosis 7.7 years. At the end of the follow-up a total of 287 children
remained autoantibody negative.
In the group of 296 autoantibody positive children, 177 were
positive only for ICA at the time of the data collection, but 17 of them
developed also biochemical islet autoantibodies during the follow-up.
A total of 45 out of the 136 children with biochemical islet
F IGURE 1 Description of the study population. Families participating in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study
were included. A total of 343 case families with a child positive for at least one islet autoantibody (Aab+) and 343 control families with an
autoantibody negative (Aab-) child matched for date of birth, sex and class II HLA risk were invited to participate the data collection of extended
family history of type 1 diabetes. At the end of follow-up the children were categorized into four groups: children remaining autoantibody
negative (Aab-), children with only classical islet cell antibodies (ICA only), children with one or more biochemical autoantibodies (Biochemical
Aab) and children who progressed to type 1 diabetes (T1D)
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autoantibodies developed type 1 diabetes by the end of the follow
up. In addition, one study subject who was positive for ICA only prog-
ressed to type 1 diabetes at the age of 13 years. This child had also
been diagnosed with steroid-resistant nephrotic syndrome and
received intermittent prednisolone therapy from the age of 9 years
and rituximab therapy from the age of 11 years. Because of the
unusual disease history this child was not included in any of the final
analyses (Figure 1).
TABLE 1 Clinical characteristics of the study population according to autoantibody (Aab) groups defined after follow-up: autoantibody
negative children, autoantibody positive children, children with islet cell antibodies only (ICA only), children with biochemical islet autoantibodies
(biochemical Aab) and children who progressed to type 1 diabetes (T1D)




negative N = 287
ICA
only N = 159
Biochemical Aab N = 136
Non-
progressors N = 91
Progressed to
T1D N = 45
Girls, N (%) 132 (46.0) 79 (49.7) 41 (45.1) 18 (40.0) .682a
Seroconversion age in years,
mean (SD)
– 4.8 (3.4) 3.4 (2.9) 2.8 (2.3) <.001b
Age in years at data collection,
mean (SD)
7.0 (4.0) 6.8 (4.1) 6.5 (3.9) 5.1 (2.7) .001c
Follow-up time in years, mean (SD) 10.1 (0.8) 10.9 (1.0) 10.9 (1.1) 3.6 (2.8) <.001d
Autoantibody profile at seroconversion
ICA only, N (%) – 159 (100) 14 (15.4) 3 (6.7)
Single first biochemical Aab, N (%) – – 68 (74.4) 16 (35.5)
IAA only, N – – 38 6
GADA only, N – – 27 6
IA-2A only, N – – 1 3
ZnT8A only, N – – 2 1
Multiple biochemical Aab, N (%) – 9 (9.9) 26 (57.8)
IAA, N – – 7 22
GADA, N – – 8 20
IA-2A, N – – 4 16
ZnT8A, N – – 1 5
Autoantibody profile during follow-up
ICA only, N (%) – 159 (100) 0 0
Single biochemical Aab, N (%) – 63 (69.2) 2 (4.4)
IAA only, N – – 37 1
GADA only, N – – 21 1
IA-2A only, N – – 3 0
ZnT8A only, N – – 2 0
Multiple biochemical Aab, N (%) – – 28 (30.8) 43 (95.6) <.001e
Two biochemical Aab in the same
sample, N (%)
– – 16 (17.6) 6 (13.3) .476e
Three biochemical Aab in the same
sample, N (%)
– – 7 (7.7) 11 (24.4) .008e
Four biochemical Aab in the same
sample, N (%)
– – 5 (5.5) 26 (57.8) <.001e
aExact Chi-square test.
bANOVA: Welch test. Post hoc pairwise Games-Howell: ICA only vs non-progressors, P = .002; ICA only vs T1D, P < .001.
cANOVA: Welch test. Post hoc pairwise Games-Howell: Autoantibody negative vs T1D, P < .001; ICA only vs T1D, P = .008.
dANOVA: Welch test. Post hoc pairwise Games-Howell: T1D vs other groups, P < .001 in all comparisons.
eSND test.
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In the group of 295 children positive for any islet autoantibody
the mean age at seroconversion was 4.1 years (SD 3.2; range
0.2-15.2 years). The children who developed biochemical autoanti-
bodies and those who progressed to type 1 diabetes were signifi-
cantly younger at seroconversion when compared to children with
ICA only (3.4 years and 2.8 years vs 4.8 years) (Table 1). Autoantibody
profiles at seroconversion varied considerably in the 136 children
who developed biochemical islet autoantibodies, both in children who
progressed to type 1 diabetes and those who remained autoantibody
positive through the follow-up (Table 1). Multiple biochemical autoan-
tibodies were present at seroconversion in 57.8% of the subjects who
progressed to type 1 diabetes, and 95.6% of progressors became
multipositive before diagnosis. The mean age at diagnosis of type
1 diabetes was 8.7 years (SD 4.5; range 1. 9-20.7) among the 45 pro-
gressors. All of them carried an HLA risk genotype: 17.8% had the
high risk HLA genotype, 60.0% moderate risk, and 22.2% slightly
increased HLA genotypes. The children who were at some point posi-
tive for 3 to 4 biochemical autoantibodies were younger at diagnosis
than those with only 1 to 2 biochemical autoantibodies (mean 7.7 vs
13.2 years, difference 5.5 years, 95% CI 2.3 to 8.6 years, P = .001).
There were five adolescents diagnosed after the age of 15 years, and
four of them had been GADA positive at seroconversion. One of them
had GADA as single biochemical autoantibody through the follow-up
(age at diagnosis 20.7 years). The other two tested positive for GADA
only at seroconversion (age at diagnosis 17.5 and 16.9 years) but
developed multiple autoantibodies during follow-up. The remaining
two subjects were multipositive at seroconversion (age at diagnosis
16.1 and 18.4 years).
2.4 | Extended family history of type 1 diabetes
Structured questionnaires inquiring the family history of diabetes
were given to the families at the DIPP visit or sent to the parents
by mail. First, the families were asked to fill in the questionnaire.
The study nurse contacted the family by phone within 1 to
2 weeks and ensured that all the questions had been understood
correctly and answered as completely as possible. The families
were systematically asked about the presence of diabetes in the
siblings, parents, grandparents, aunts, uncles, cousins, and other
relatives of the DIPP child. The type of diabetes (type 1, type 2 or
gestational diabetes as reported by the parents), the age at diagno-
sis, and the mode of treatment (diet, oral medication and/or insu-
lin) were recorded.
The study was approved by the ethics committee of Oulu
University Hospital. All participating families provided written
informed consent.
2.5 | Statistical analyses
The distributions of categorical variables were compared using exact
Pearson's chi-squared test. Proportions between two groups were
tested by the Standardized Normal Deviate (SND) test. Comparisons
of means between two groups were done by Student's t test and
between more than two groups by Welch's ANOVA test with Games-
Howell procedure for post hoc multiple comparisons correction. Data
analysis was performed with the IBM SPSS for Windows (version 25)
statistical software (Armonk, NY; IBM Corp.) and StatsDirect statisti-
cal software (StatsDirect Ltd, England).
2.6 | PATIENT CONSENT STATEMENT
All participating families provided written informed consent.
3 | RESULTS
A total of 214 children (36.8%) had at least one relative with type
1 diabetes in the extended family or in the nuclear family. We com-
pared the frequency of type 1 diabetes in the families between four
groups of children: progressors with biochemical autoantibodies, non-
progressors with biochemical autoantibodies, non-progressors with
ICA only, and autoantibody negative children. There were statistically
significant differences in the extended family history of type 1 diabe-
tes between children who progressed to type 1 diabetes and those
who remained non-diabetic (Table 2). The majority of progressors had
at least one relative with type 1 diabetes (62.2%), whereas in the
other groups the proportions were clearly lower. The lowest propor-
tion of children with a relative with type 1 diabetes was observed in
the autoantibody negative group (32.4%). When including only rela-
tives outside the nuclear family the difference between the groups
remained statistically significant (Table 2). A similar trend was
observed in the nuclear family, particularly when type 1 diabetes in
the father was analyzed.
Interestingly, the number of child's biochemical autoantibodies
was significantly associated with the presence of type 1 diabetes in
any relatives (Tables 3 and 4). Children with 2 to 4 biochemical auto-
antibodies had more often a positive family history of type 1 diabetes
(57.7%) compared to children with a single biochemical autoantibody
(32.3%) (P = .002; Table 3). Particularly, this effect was present when
analyzing the paternal extended family (32.2% vs 13.8%, P = .010).
Furthermore, children with multiple biochemical autoantibodies had
more often relative(s) with type 1 diabetes outside the nuclear family
when compared to those with a single biochemical autoantibody
(P = .006; Table 3). When only nuclear family was considered (Tables
3-4), children with multiple autoantibodies had more often a father,
mother or sibling with type 1 diabetes than children with single posi-
tivity (P = .019; Table 3).
Maternal type 1 diabetes was associated with younger serocon-
version age of the child when compared to those children without
maternal type 1 diabetes (2.0 vs 4.1 years; difference 2.2, 95% CI 1.2
to 3.2, P = .001). Paternal type 1 diabetes was not significantly associ-
ated with seroconversion age of the child (2.9 vs 4.1 years in children
with and without paternal type 1 diabetes, respectively; difference
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1.2, 95% CI -1.1 to 3.4, P = .314). In children with multiple islet auto-
antibodies (n = 71) the age at the appearance of multiple antibodies
was not affected by family history of type 1 diabetes (4.1 years vs
4.6 years in children with and without any relative with type 1 diabe-
tes; P = .557). Neither was the age at initial seroconversion in
multipositive children affected by family history (3.1 years for children
who had at least one relative with type 1 diabetes and 3.3 years for
those who had no relatives with type 1 diabetes; P = .519).
IAA and GADA were compared as the first appearing islet auto-
antibody and also as the single biochemical autoantibody during
follow-up (Table 5). No differences in the frequency of IAA only or
GADA only at seroconversion were observed when comparing chil-
dren in various family history groups. Neither were any differences
seen for IAA only and GADA only during follow-up between these
groups.
Other types of diabetes were also reported. In the nuclear fami-
lies, two mothers and three fathers of autoantibody negative children
had type 2 diabetes. In addition, one father of a child with ICA only
had type 2 diabetes. However, the 136 children with biochemical
autoantibodies had no first-degree relatives with type 2 diabetes.
When including all relatives outside the nuclear family, a positive fam-
ily history of type 2 diabetes was very common in the study children
(80.8%). There were no differences in the extended family history of
type 2 diabetes between children without autoantibodies, with ICA
only, non-progressors with biochemical autoantibodies and pro-
gressors (84.0% vs 76.1% vs 76.9% vs 84.4%, respectively).
Seventy-nine mothers (13.6%) had been diagnosed with gesta-
tional diabetes in at least one pregnancy. The proportions of study
children with such a mother were similar in the above mentioned four
groups (14.3%, 13.2%, 14.3%, and 8.9%; respectively)
TABLE 2 Family history of type 1 diabetes (T1D) in various groups: autoantibody negative children, autoantibody positive children, children
with islet cell antibodies only (ICA only), children with biochemical islet autoantibodies (biochemical Aab) and children who progressed to T1D.
Number and percentage of children having at least one relative with T1D is given Comment by Riitta Veijola when reading the proofs: Please
correct data lines 6-11 and 14-19 to be located lower to fit with the corresponding text in the left column. e.g. 7 (2.4) should match with T1D in
maternal grandparents




negative N = 287
ICA
only N = 159
Biochemical Aab N = 136
Non-
progressors N = 91
Progressed to
T1D N = 45
Sibling with T1D, N (%) 0 3 (1.9) 3 (3.3) 1 (2.2) .049
Mother with T1D, N (%) 2 (0.7) 3 (1.9) 3 (3.3) 1 (2.2) .328
Father with T1D, N (%) 9 (3.1) 2 (1.3) 2 (2.2) 4 (8.9) .053
T1D in the nuclear family, N (%) 11 (3.8) 8 (5.0) 7 (7.7)a 5 (11.1)b .152
T1D in the maternal extended familyc, N (%)
T1D in maternal grandparents
T1D in maternal great grandparents
T1D in maternal grandparents' siblings
T1D in mother's siblings
T1D in child's maternal cousins




































T1D in the paternal extended familyc, N (%)
T1D in paternal grandparents
T1D in paternal great grandparents
T1D in paternal grandparents' siblings
T1D in father's siblings
T1D in child's paternal cousins




































T1D in any relatives outside the nuclear
family, N (%)
88 (30.7) 56 (35.2) 32 (35.2) 26 (57.8) .005e
T1D in both nuclear family and extended
family, N (%)
93 (32.4) 59 (37.1) 34 (37.4) 28 (62.2) .002f
Note: Nuclear family includes full siblings, the mother and the father.
aIn one family both the father and the sibling had T1D.
bIn another family both the mother and the father had T1D.
cIncluding the mother or the father.
dExact Chi square test was used in all comparisons between the four groups.
ePairwise SND tests: Autoantibody negative vs T1D, P < .001; ICA only vs T1D, P = 0.006; Non-progressors vs T1D, P = 0.011.
fPairwise SND tests: Autoantibody negative vs T1D, P < .001; ICA only vs T1D, P = 0.002; Non-progressors vs T1D, P = 0.007.
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4 | DISCUSSION
In the prospective DIPP study that follows children with HLA con-
ferred susceptibility from birth, we demonstrate that a positive
extended family history of type 1 diabetes is associated with
increased risk of islet autoimmunity, the number of biochemical auto-
antibodies and development of type 1 diabetes. In particular, our data
shows for the first time that type 1 diabetes in relatives outside the
nuclear family is a significant risk factor for islet autoimmunity and
progression to clinical disease in HLA susceptible children.
Earlier studies have reported relatively constant proportions of
patients with type 1 diabetes who have first degree relatives with the
disease, 10% to 13% at the time of diagnosis of the index case.18-21
Only very few earlier studies have explored the role of extended fam-
ily history of type 1 diabetes. In Finland 21.8% of children with newly
diagnosed type 1 diabetes have at least one affected first- and/or
TABLE 3 Family history of type 1 diabetes (T1D) in two groups of DIPP children with biochemical autoantibodies according to the maximal
number of biochemical autoantibodies during follow-up. Both progressors and non-progressors are included. Number and percentage of children
having at least one relative with T1D is given
1 Biochemical Aab N = 65 2–4 Biochemical Aab N = 71 P value
Sibling with T1D, N (%) 1 (1.5) 3 (4.2) .371
Mother with T1D, N (%) 1 (1.5) 3 (4.2) .371
Father with T1D, N (%) 0 6 (8.5) .014
T1D in the nuclear family, N (%) 2 (3.1) 10 (14.1)b/c .019
T1D in the maternal extended familya, N (%) 14 (21.5) 20 (28.2) .336
T1D in the paternal extended familya, N (%) 9 (13.8) 23 (32.2) .010
T1D in any relatives outside the nuclear family, N (%) 20 (30.8) 38 (53.5) .006
T1D in any relatives (nuclear family and extended
family included), N (%)
21 (32.3) 41 (57.7) .002
Note: Nuclear family includes full siblings, the mother and the father. SND test was used in all comparisons.
aIncluding the mother or the father.
bIn one family both the father and the sibling had T1D.
cIn one family both the mother and the father had T1D.
TABLE 4 Family history of type 1 diabetes (T1D) in four groups of DIPP children with biochemical autoantibodies according to the maximal
number of biochemical autoantibodies during follow-up. Number and percentage of children having at least one relative with T1D is given
Children with Biochemical Aab including both non-progressors and subjects who progressed to
T1D N = 136
1 Biochemical
Aab N = 65
2 Biochemical
Aab N = 22
3 Biochemical
Aab N = 18
4 Biochemical
Aab N = 31 P valued
Sibling with T1D, N (%) 1 (1.5) 2 (9.1) 1 (5.6) 0 .172
Mother with T1D, N (%) 1 (1.5) 1 (4.5) 1 (5.6) 1 (3.2) .896
Father with T1D, N (%) 0 1 (4.5) 3 (16.7) 2 (6.5) .018
T1D in the nuclear family, N (%) 2 (3.1) 3 (13.6)a 4 (22.2)b 3 (9.7) .054
T1D in the maternal extended familyc, N (%) 14 (21.5) 5 (22.7) 6 (33.3) 9 (29.0) .703
T1D in the paternal extended familyc, N (%) 9 (13.8) 10 (45.5) 8 (44.4) 8 (25.8) .005e
T1D in any relatives outside the nuclear
family, N (%)
20 (30.8) 11 (50.0) 12 (66.7) 15 (48.4) .030f
T1D in any relatives (nuclear family and
extended family included), N (%)
21 (32.3) 13 (59.1) 12 (66.7) 16 (51.6) .018g
Note: Nuclear family includes full siblings, the mother and the father.
aIn one family both the father and the sibling had T1D.
bIn one family both the mother and the father had T1D.
cIncluding the mother or the father.
dExact Chi square test was used in all comparisons between the four groups.
ePairwise SND tests: 1 Biochemical Aab vs 2 biochemical Aab, P = 0.003; 1 Biochemical Aab vs 3 biochemical Aab, P = .005.
fPairwise SND tests: 1 Biochemical Aab vs 3 biochemical Aab, P = .007.
gPairwise SND tests: 1 Biochemical Aab vs 2 biochemical Aab, P = .026; 1 Biochemical Aab vs 3 biochemical Aab, P = .008; 1 Biochemical Aab vs 4
biochemical Aab, P = .053.
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second-degree relative. In a large series from the Finnish Pediatric
Diabetes Register a total of 9.9% of the cases had affected first
degree relative(s), 9.5% had affected second degree relative(s) (ie,
either grandparent or sibling of the parent), and 2.4% had both first
and second degree relatives with type 1 diabetes.22 However, third
degree relatives (ie, cousins, siblings of grandparents and their chil-
dren, great grandparents) were not taken into account. In a smaller
Finnish series of children with type 1 diabetes 54.0% of the cases had
at least one affected relative when first, second and third degree rela-
tives were included, compared to 32.5% of matched non-diabetic chil-
dren.23 In the current study population 36.8% of children initially
selected for DIPP follow-up had at least one relative with type 1 dia-
betes in the whole extended family, and the proportion was remark-
ably higher (62.2%) in those who developed biochemical islet
autoantibodies and progressed to type 1 diabetes. A surprisingly high
proportion of progressors (57.8%) had an affected relative outside the
nuclear family. Among autoantibody negative DIPP children the pro-
portion of those with any relative with type 1 diabetes in the
extended family was 32.4%, very similar to the findings by Alhonen
et al. in the general childhood population in Finland.23 It is noteworthy
that the DIPP children represent HLA selected high risk population
whereas the Finnish Pediatric Diabetes Register and the study by
Alhonen et al.23 also included cases with other class II HLA genotypes.
Our novel and the most important finding was that the presence
of type 1 diabetes in the extended family was clearly more frequent
among the progressors as compared to non-progressors with bio-
chemical autoantibodies, children with ICA only, or those with no
detectable autoantibodies; also when considering only relatives out-
side the nuclear family. Interestingly, the number of various biochemi-
cal autoantibodies was significantly associated with a positive family
history of type 1 diabetes. Children with single positivity had affected
relatives as often as those without any autoantibodies, whereas those
with two to four biochemical autoantibodies had positive family his-
tory as often as the progressors. Multipositivity was associated with
paternal, but not maternal, extended family history of type 1 diabetes,
which is a novel observation and of special interest together with the
well-known fact that type 1 diabetes in the father confers higher risk
for the offspring to develop the disease compared to maternal type
1 diabetes.24 Children with either a mother or a father with type 1
diabetes (n = 7 and n = 8, respectively) were slightly younger at sero-
conversion than other children, although the difference was statisti-
cally significant only for maternal type 1 diabetes. The age at
appearance of multiple autoantibodies was not affected by family his-
tory of type 1 diabetes.
In the group of progressors 43/45 (95.6%) were positive for mul-
tiple biochemical islet autoantibodies and seroconversion age was sig-
nificantly younger than in the other autoantibody positive children.
This is in line with earlier studies reporting that young age at serocon-
version is associated with rapid progression to clinical disease.7 On
the other hand, only 28/91 (30.8%) of non-progressors with biochem-
ical autoantibodies were multipositive, while 63/91 (69.2%) tested
positive for a single autoantibody. Non-progressors also had less often
any family member with type 1 diabetes, and therefore it can be spec-
ulated that a lower family burden and thereby perhaps weaker genetic
risk protects the child from the development of multiple autoanti-
bodies and the disease. Earlier studies have shown that children with
a single autoantibody have remarkably lower risk for development of
type 1 diabetes during follow-up for 10 to 15 years compared to
those with multiple islet autoantibodies.2
The strength of this study lies in the systematically collected
extended family history data from families participating in the pro-
spective DIPP study, including also third degree relatives. The follow-
up time of the children was relatively long, more than 10 years in
participants who did not progress to type 1 diabetes. Our study
TABLE 5 Number of children with biochemical autoantibodies and IAA or GADA as the first autoantibody at seroconversion, or as the only
autoantibody during follow-up. Data is shown according to the family history of type 1 diabetes (T1D)
At seroconversion During the follow-up
IAA first N = 44 GADA first N = 33 P value IAA only N = 37 GADA only N = 22 P value
Sibling with T1D, N (%) 2 (4.5) 1 (3.0) 0.999 1 (2.7) 0 (0) .999
Mother with T1D, N (%) 1 (2.2) 1 (3.0) 0.999 0 (0) 1 (4.5) .186
Father with T1D, N5 1 (2.2) 0 (0) 0.999 0 (0) 0 (0)
T1D in the nuclear family, N (%) 3 (6.8) 2 (6.1) 0999 1 (2.7) 1 (4.5) .999
T1D in the mother's family, N (%) 12 (27.3) 11 (33.3) 0.471 6 (16.2) 8 (36.4) .070
T1D in the father's family, N (%) 10 (22.7) 4 (12.1) 0.252 6 (16.2) 2 (9.1) .467
T1D in any relative outside the
nuclear family, N (%)
18 (40.9) 12 (36.4) 0.647 11 (29.7) 8 (36.4) .581
T1D in any relative, N (%) 19 (43.2) 14 (42.4) 0.999 11 (29.7) 9 40.9) .287
Note: SND test was used in all comparisons.
Abbreviations: GADA, antibodies against glutamic acid decarboxylase; IAA, insulin autoantibody; SND, standardized normal deviate.
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population included also autoantibody positive children who were
followed beyond age 15 years, and a total of five subjects were diag-
nosed after that age. One major asset was that we collected family
history data also from DIPP children remaining autoantibody negative
and both groups were followed in parallel.
A limitation was that even though the family history data were
based on both structured questionnaires and interviews by a trained
nurse, the parents may have had inaccurate or inadequate knowledge
about disease history in the extended family. We only recorded the
diagnoses that the parents considered reliable. However, in some
cases there might have been misclassification between type 1 and
type 2 diabetes. In the current series we were not able to explore the
relationship between family history of type 1 diabetes and class II
HLA genotype, because the DIPP study is focused on follow-up of
children with increased HLA-conferred risk.
Type 1 diabetes is currently not preventable, but our knowledge
about predictive markers has greatly improved with the data from
prospective birth cohort studies.5,6 In addition, type 1 diabetes
genetic risk scores (GRS) which have recently been developed have
been shown to improve prediction of the disease.25 We anticipate
that in the future the combination of population specific GRS and
extended family history could still improve the prediction of islet auto-
immunity and type 1 diabetes.
In conclusion, our data demonstrates that in addition to type
1 diabetes in the nuclear family, the presence of the disease in rela-
tives outside the nuclear family, particularly in the paternal family, is
associated with development of multiple islet autoantibodies and pro-
gression to type 1 diabetes in children at genetic risk. Future studies
should include collection of data from the extended family of subjects
at risk for type 1 diabetes.
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